Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat

Neurobiology of Disease

Volumn 50, Issue 1, 2013, Pages 142-150

  Breger, Ludivine S ^a,b   Dunnett, Stephen B ^b   Lane, Emma L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

AIM; LID; Parkinson disease; Rodent; Rotation; Stereotypy

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMANTADINE; LEVODOPA; OXIDOPAMINE; RACLOPRIDE;

3 ABNORMAL INVOLUNTARY MOVEMENT RATING SCALE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; DYSKINESIA; EXPERIMENTAL RAT; FEMALE; FOREBRAIN; INTERMETHOD COMPARISON; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RATING SCALE; RELIABILITY; SCORING SYSTEM; STEREOTYPY; STEREOTYPY SCALE;

ADRENERGIC AGENTS; AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX;

EID: 84868462682     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.10.013     Document Type: Article

References (50)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
2. Andersson M., et al. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
3. Barbeau A. l-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can. Med. Assoc. J. 1969, 101:59-68.
4. Bido S., et al. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J. Neurochem. 2011, 118:1043-1055.
5. Blanchet P.J., et al. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 1998, 13:798-802.
6. Carta M., et al. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 2006, 96:1718-1727.
7. Cenci M.A., et al. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
8. Cenci M.A., et al. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev. Neurosci. 2002, 3:574-579.
9. Colosimo C., et al. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov. Disord. 2010, 25:1131-1142.
10. Creese I., Iversen S.D. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res. 1973, 55:369-382.
11. da Silva-Junior F.P., et al. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat. Disord. 2005, 11:449-452.
12. Dekundy A., et al. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
13. Ervin G.N., et al. Different behavioral responses to L-DOPA after anterolateral or posterolateral hypothalamic injections of 6-hydroxydopamine. Brain Res. 1977, 132:507-520.
14. Fahn S., Elton R.L., Members of the UPDRS Development Committee Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease 1987, vol. 2:153-163. Macmillan Health Care Information, Florham Park, New Jersey, 293-304.
15. Fog R. Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs. Psychopharmacologia 1969, 14:299-304.
16. Fox S.H., et al. A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Mov. Disord. 2012, 27(11):1373-1378.
17. Goetz C.G., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008, 23:2129-2170.
18. Goetz C.G., et al. Temporal stability of the Unified Dyskinesia Rating Scale. Mov. Disord. 2011, 26:2556-2559.
19. Imbert C., et al. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J. Neurosci. Methods 2000, 96:71-76.
20. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003, 61:S4-S11.
21. Jolkkonen J., et al. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res. Mol. Brain Res. 1995, 32:297-307.
22. Katzenschlager R., et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology 2007, 69:555-563.
23. Lane E.L., et al. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol. Dis. 2008, 32:220-228.
24. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov. Disord. 2004, 19:743-754.
25. Lindgren H.S., et al. Putaminal upregulation of FosB/delta-FosB-like. Immunoreactivity in Parkinson's disease patients with dyskinesia. J. Park. Dis. 2011, 1:347-357.
26. Lundblad M., et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
27. Lundblad M., et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 2005, 194:66-75.
28. Lyon M., Robbins T. The Action of Central Nervous System Stimulant Drugs: A General Theory Concerning Amphetamine Effects 1975, Spectrum, New York.
29. Manson A.J., et al. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 2000, 15:336-337.
30. Maries E., et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol. Dis. 2006, 21:165-180.
31. Mela F., et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 2007, 101:483-497.
32. Monville C., et al. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 2005, 68:16-23.
33. Monville C., et al. Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. Brain Res. Bull. 2009, 78:248-253.
34. Munoz A., et al. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol. 2009, 219:298-307.
35. Olanow C.W., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
36. Papathanou, M., Continuous dopaminergic stimulation and the expression of AIMs in L-DOPA-lesioned rats. Pharmacology, Vol. PhD thesis. King's College London, London, 2010, pp. 228.
37. Pearce R.K., et al. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov. Disord. 1995, 10:731-740.
38. Petzinger G.M., et al. Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate. Mov. Disord. 2001, 16:202-207.
39. Pinna A., et al. Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav. Brain Res. 2006, 171:175-178.
40. Randrup A., et al. Adrenergic mechanisms and amphetamine induced abnormal behaviour. Acta Pharmacol. Toxicol. 1963, 20:145-157.
41. Rylander D., et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 2010, 39:352-361.
42. Smith G.A., et al. Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats. Neuropharmacology 2012, 63(5):818-828.
43. Smith G.A., et al. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia. Behav. Brain Res. 2012, 226:281-292.
44. Steece-Collier K., et al. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov. Disord. 2003, 18:1442-1454.
45. Taylor J.L., et al. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav. 2005, 81:887-893.
46. Torres E.M., et al. Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates. J. Neurosci. Methods 2011, 200:29-35.
47. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24(3):485-493. (Dec 18).
48. Winkler C., et al. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
49. Wolf E., et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov. Disord. 2010, 25:1357-1363.
50. Wong K.K., et al. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Mov. Disord. 2011, 26:1552-1555.